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Summary Eighteen patients with liver metastasis or locoregional recurrence of colon carcinoma received
locoregional treatment by continuous 5-day infusions of 5-FU. 5-FU blood levels were measured by HPLC
every day of the cycle at 8 am and 5 pm for a total of 87 cycles. Twelve patients were given the drug by an
intra-arterial hepatic (i.a.h.) route, 3 by the portal vein (i.p.v.) and 3 by an intra-arterial pelvic (i.a.p.) route.
These three routes were compared in respect of their relative pre-systemic drug uptake and the effect of dose
escalation. Both the i.a.h. and i.p.v. routes, but not the i.a.p. route, resulted in a significant reduction in
AUCO-lo5h compared to the i.v. route at the same dose range. Increasing the dose led to a modification in
circulating 5-FU levels proportional to the dose for the i.v. and i.a.p. routes. By contrast, for the i.a.h. and
i.p.v. routes, systemic drug delivery was significantly elevated, out of proportion with the dose, indicating a
saturable process. For the i.a.h. route, increasing the 5-FU dose from 780 to 1000mgm-2day-1 caused a
drop in hepatic extraction from 0.93 (0.90-0.95) to 0.44 (0.21-0.66). Liver saturation mechanisms were also
evidenced by a mean increase of 2.6 times for the circulating drug level during the second part of the cycle as
compared to the first part (P<0.001). The evolution of 5-FU AUClo5h as a function of the dose was
exponential (r=0.75, P<0.001). Local extraction consecutive to i.a.p. was non-existent, implying that this
route ofdrug administration has no potential advantage over classical i.v. infusion.
Locoregional chemotherapy has the dual aim of
increasing the exposure of tumor-bearing areas to
drugs while partially reducing the cytotoxic effects
on the patient's healthy tissues (Ansfield et al., 1971;
Ensminger et al., (1978). The recent interest shown
in this therapeutic approach can be explained by
better knowledge about pharmacokinetics, allowing
more objective and rational use of drugs (Balis
et al., 1983; Schabel et al., 1983) and by bio-
technological progress in the field of implantable
pumps (Blackshear et al., 1972) permitting chemo-
therapy infusions on an ambulatory basis.
Fluoropyrimidines represent the predominant
class of drugs used for locoregional chemotherapy
of colorectal cancer (Davis, 1982). Long clinical
experience has been gained with chemotherapy
protocols administered by an intra-arterial hepatic
(i.a.h.) route (Ansfield et al., 1971; Stagg et al.,
1984; Ensminer et al., 1978). Use of the portal vein
appears advisable for small liver metastases
(Ackerman et al., 1969). Immediate post-surgery
infusion of 5-flourouracil (5-FU) in the portal vein
has recently been shown to significantly reduce the
rate of disease recurrence at two years for Dukes' C
lesions (Taylor et al., 1979). Ensminger et al. (1978)
have published detailed pharmacokinetic data
concerning the i.a.h. administration of 5-FU, but
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for short infusions (40 to 60min) at dose rates 10-
100 times higher than those usually used. Their
conclusions are thus difficult to extrapolate to
continuous 5-day infusions which are the most
commonly used regimens today (Petrek et al., 1979;
Stagg et al., 1984). Only indirect pharmacokinetic
data are available for intra-portal (i.p.v.) 5-FU
infusion. However, Speyer et al. (1981) and Gyves
et al. (1984), on the basis of i.p. 5-FU adminis-
tration, suggested that considerable hepatic 5-FU
extraction might occur through portal vein
circulation. No pharmacokinetic evaluations have
been published to date concerning intra-arterial
pelvic (i.a.p.) 5-FU treatment aimed at better
control of locoregional recurrences of colorectal
cancer.
This study present pharmacokinetic data
collected for 18 patients with liver metastasis or
locoregional recurrence of colorectal cancer treated
by continuous 5-day regional infusion of 5-FU.
(i.a.h.), i.p.v. and i.a.p. routes were compared at
increasing drug doses.
Materials and methods
Patients
All 18 patients (13 male, 5 female) had histo-
logically confirmed colorectal cancer. Mean patients
age was 65 years (range 57-78). Three of the
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patients had only locoregional disease recurrence;
the other 15 had liver metastasis but no pelvic
recurrence. Twelve patients were treated by the
i.a.h. route, 3 by the i.p.v. route, and 3 by the i.a.p.
route. Criteria for inclusion in the study were: esti-
mated survival of >3 months, performance status
.2 (ECOG), no ascites neutrophilic polynuclear
cells >2500mm- , platelets > 100,000mm-3,
and total bilirubin < 1.5mgdl 1
Catheter insertion
Catheters were inserted using an axillary or femoral
artery route under local anesthesia. The tip of the
catheter was placed in the hypogastric artery for
patients with pelvic recurrences and in the hepatic
artery for patients with liver metastasis. Three
patients underwent surgery for insertion of a
catheter in the portal vein, via the ombilical vein.
Angiographic controls were performed sys-
tematically, during each cycle, prior to the start of
5-FU infusion.
Chemotherapy protocols
5-FU (Roche, France) was given by continuous 5-
day infusion at doses varying from 500 to
1650mgm-224h-. The daily dose of 5-FU was
diluted in 21 of 5% dextrose in water (D5W) using
an external delivery pump (Fresenius, France). No
other concurrent treatments were administered.
Antiemetics were not used. The interval between
the start of two successive cycles was 4 weeks. A
total of 87 cycles was analyzed, 17 of which
concerned 5-FU administered by a peripheral
venous route (i.v.). In an attempt to simplify data
presentation, 5-FU doses were classed in two
groups: conventional doses: 500-900mgm-224h -
and high doses: 900-1650mgm-224h -1.
Pharmacokinetics
Blood samples were obtained every day of each
cycle at 8am and 5pm, i.e. at Oh, 9h, 24h, 33h,
48h, 57h, 72h, 81h, 96h and 105h. Samples (5ml
on EDTA tubes) were rapidly transferred to the
laboratory. After centrifugation (10min, 4°C,
2500rpm), the supernatant was frozen at -200C
until analysis. Plasma 5-FU measurement was
performed by HPLC (Christophidis et al., 1979);
the limit of sensitivity was 5ngml-1. The day-to-
day variation coefficient evaluated for 14 different
analyses of a plasma spiked with 100ngml-l was
4% (sd/mean x 100). The trapezoidal rule was used
to compute the area under the curve (AUC) for the
entire cycle, i.e. AUC010osh5 Based on the
theoretical considerations described by Chen &
Gross (1980), the local extraction parameter was
defined as follows:
loca ~[AUCO-s lOSh 1
local extraction ==1-LAUCO-105hRiv
where AUCo-1oShi-v- =area under the curve after
peripheral intravenous
administration
and AUClo05hR =area under the curve after
regional administration (i.a.h.
or i.a.p. or i.p.v.) of the same
dose as given by i.v.
This parameter was only evaluated for patients who
received 5-FU i.v. infusions in cycles just before
locoregional treatment.
Results
Table I gives the respective values of the areas
under the plasma concentration x time curve
(AUC>losh) for the different sites of locoregional 5-
FU treatment. Data collected for i.v. infusions of 6
patients in the study have been shown as control
values, corresponding to systemic circulating 5-FU
levels when the drug is administered directly into
the general circulation. Intra-hepatic (i.a.h. and
i.p.v.) administration of 5-FU appears to sig-
nificantly reduce the circulating levels of the drug as
compared to the values observed following i.v.
infusion. By contrast, no significant change was
noted in AUC-losh between i.a.p. and i.v. infusions.
Increasing the 5-FU dose led to different
modifications in pharmacokinetics, depending on
the route of drug administration. Thus, for i.v. and
i.a.p., the mean 5-FU circulating levels rose
proportionately with the dose increase. By contrast,
the AUCo105h values for i.a.h. and i.p.v. increased
out of proportion to dose increases, and significant
differences were noted between conventional and
high 5-FU doses. Figure 1 details the changes
observed in the i.a.h. and i.p.v. groups for both
intra- and inter-cycle drug levels. Circulating 5-FU
blood levels were 2.6 times higher during the second
half of the cycle than during the first half
(P<0.001); Figure l(a) presents the typical profile
for 5 patients. A saturation mechanism is also
perceptible when the evolution of AUClO05h is
considered as a function of the dose (Figure 1(b)):
5-FU AUColosh is linked to the dose by an
exponential function (r=0.75, P<0.O01). A dose of
lOOOmgm-2 day-' appears to be the critical
threshold value above which wide inter-patient
variations become patent.
Table II presents the estimated local extraction
values for patients who received 5-FU by i.v.
infusion prior to locoregional treatment at the same
dose. With conventional doses, hepatic extraction5-FU PHARMACOKINETICS DURING LOCOREGIONAL TREATMENT 17
Table I Systemic 5-FU exposure after i.v. and locoregional administration.
Mean 5-FU AUC-0osh Statistical analysis
No. of No. of doses ngml-1h
patients' cycles mg24-1 h (s.d.) mean (s.d.) Seefootnote' Seefootnotec
Intravenous 5-FU
conventional
dosesd
high doses
ratio'
Intra-arterial hepatic 5-FU
conventional
doses I
high doses
ratio
5 13 780 (93)
4 4 954 (27)
1.22
11 18 804 (96)
7 34 1280(230) 12,800(8400)
1.59
Intra-portal 5-FU
conventional
doses
high doses
3 5 804 (16)
2 4 1110(163)
ratio 1.38
1560(1110)
t=3.43
df=7
9550(5150) 0.01 <P<0.02
6.12
2 5 677 (99) 16,400(5100)
1 4 1058 (68) 19,800(5800)
1.56
t=0.89
df=7
NS
1.21
aCertain patients were in both 5-FU dose groups.
bStudent's t-test for comparison of AUC between conventional and high doses.
cStudent's t-test for comparison of AUC with corresponding i.v. control group.
dConventional and high doses as defined in Materials and methods.
eRatios of mean values determined at high doses/conventional doses.
was high (mean 0.93) for the 3 patients evaluated;
by contrast, increasing doses led to a drop in
hepatic uptake (0.21 and 0.66 for the 2 patients
evaluated). In comparison, and in confirmation of
the data in Table I, i.a.p. administration of 5-FU
did not involve pre-systemic extraction.
Discussion
Existence of a dose/response relationship is one of
the criteria for selection of anticancer agents for
locoregional treatment (Ensminger & Gyves, 1984).
Experimentally, 5-FU appears to fulfil this
condition (Schabel et al., 1983). On this basis,
increasing local drug exposure can reasonably be
expected to have a high probability of causing more
quantitative regression than an equivalent dose
administered by a venous route. The data in the
present study were collected during the normal
course of different types of locoregional treatment
with 5-FU for patients with colorectal cancer. With
t=1.9
df=15
NS
14,000(8000)
22,400(7300)
1.60
4030(3600)
t=4.18
df=50
P<0.001
3.78
t=3.93
df=29
P<0.001
t=2.17
df=36
0.02<P<0.05
Intra-arterial
pelvic 5-FU
conventional
doses
high doses
t=3.06
df=16
0.001 <P<0.01
t=2.88
df=6
0.02<P<0.05
ratio
t=0.59
df=16
NS
t=0.58
df=6
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Figure 1 Intra-cycle (a) and inter-cycle (b) evolution of 5-FU blood concentrations for intrahepatic 5-day
infusions. * =i.a.h., O =i.p.v.
The daily 5-FU doses (mg) for patients in (a) were: Fo: 1250; Hu: 1500; De: 850; Gu: 1000; Le: 810. All
cycles i.a.h. and i.p.; AUC part II/AUC part I: mean 2.6; s.d. 1.9; P<0.001. (Wilcoxson's test for 61 paired
samples).
The heavy line in (b) represents the exponential function: AUCngml-1h= -ab dose (mgm-2) where:
a =324.8; b =2.66 x 10-3; (r =0.75, P<0.0001).
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conventional doses (500-900mgm 224h- 1 x 5
days), direct 5-FU infusion into the liver resulted in
elevated local extraction (over 0.90), with lower
AUC values for both the intra-arterial and portal
routes than with systemic venous administration.
These observations have several implications. They
confirm the general absence of systemic toxicity
after intra-arterial chemotherapy for metastasis of
colorectal cancer to the liver (Stagg et al., 1984).
The elevated hepatic extraction values we observed
do not fully agree with those reported by
Ensminger et al. (1978), which varied from 0.22 to
0.45. This difference is probably due to the shorter
infusion times (40 to 60min) and the higher drug
delivery rates used by these last authors, which
caused the hepatic capacities for drug uptake and
metabolism to be exceeded. Our high extraction
rates are comparable to those obtained with 5-
FUDR, the fluoropyrimidine recommended for
intrahepatic treatment (Ensminger & Gyves, 1983).
We thus feel that continuous i.a.h. 5-FU infusions
may offer therapeutic advantages over rapid i.a.h.
administration.
The very low circulating 5-FU levels observed
after portal infusion indicate high pre-systemic
extraction with this route. This feature was
previously suggested by Speyer et al. (1981) and
Gyves et al. (1984) following i.p. 5.-FU adminis-
tration. This observation provides a possible ex-
planation for the clinical trial results of Taylor et al.
(1979), who reported a marked benefit for the
prevention of recurrences with adjuvant treatment
by i.p.v. 5-FU.
By contrast with liver administration, the i.a.p.
route for 5-FU gave the same circulating drug levels
as i.v. infusion (Tables I and II). On these bases,
locoregional pelvic 5-FU treatment appears to have
little advantage, if any, over classical systemic
administration of the drug. However, because of the
small number of patients in this group, these results
have only an indicative value.
With regional chemotherapy, attention must be
paid to the possibility of acute systemic drug
exposure once local drug extraction capacities have
been exceeded when drug doses are increased.
Increasing the 5-FU dose from conventional to high
levels clearly modified pharmacokinetic data,
although to different degrees depending on the
route of administration.
The AUC,O,105h values for both i.v. and i.a.p. rose
proportionally to the dose. By contrast, highly
significant differences were observed for i.a.h. and
i.p.v. infusions between conventional and high
doses. In agreement with this, individual values for
local hepatic extraction were exceeded when doses
were increased (Table II). These data may be
considered new arguments in the characterization of
the non-linear kinetics of 5-FU (Myers, 1981; Powis
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et al., 1981). Figure 1 provides details on the
saturable 5-FU hepatic uptake observed for our
patients. During infusion, intra-cycle circulating
5-FU levels were significantly higher during the
secondhalfofthecycle.This observationcorroborates
similar recent data published by Ensminger et al.
(1983). Regression analysis revealed an exponential
relationship between AUCO105h and the 5-FU dose
(r=0.75, P<0.001; Figure 1(b)). High inter-
individual variations were perceptible in
AUClo05h as a function of the dose above a
threshold value of lOOOmgm-2day-1. While this
threshold is only an indication, it may prove of
clinical importance for other investigations during
which intrahepatic 5-FU doses are increased during
patient treatment. However, the limited capacity
for hepatic biotransformation, resulting in an im-
portant non-linear elevation in systemic drug concen-
trations when 5-FU doses are increased, should
not be considered a drawback. Since the central
problem raised by locoregional chemotherapy is
extra-regional tumour growth (Aronsen et al., 1979;
Stagg et al., 1984), appreciable diffusion of 5-FU
only when local hepatic capacities have been
exceeded could potentially control extra-hepatic
disease evolution. Individual evaluations of pharma-
cokinetic parameters such as AUC might thus be
very useful for adjustment of the 5-FU dose
administered locally to the liver; this would permit
both increased locoregional drug exposure and
systemic protection due to cytotoxic circulating
5-FU concentrations. This is the basis of an ongoing
pharmaco-clinical trial at our institution concerning
i.a.h. 5-FU treatment.
The authors wish to thank Nancy Rameau for translation
and preparation of the manuscript.
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